Search Results - "Proksch, Joel"

Bardoxolone methyl analog attenuates proteinuria‐induced tubular damage by modulating mitochondrial function by Nagasu, Hajime, Sogawa, Yuji, Kidokoro, Kengo, Itano, Seiji, Yamamoto, Toshiya, Satoh, Minoru, Sasaki, Tamaki, Suzuki, Takafumi, Yamamoto, Masayuki, Wigley, W. Christian, Proksch, Joel W., Meyer, Colin J., Kashihara, Naoki

“…Multiple clinical studies have shown that bardoxolone methyl, a potent activator of nuclear factor erythroid 2‐related factor 2 (Nrf2), is effective in…”
Get full text

Topical Application of the Synthetic Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis by Reisman, Scott A., Lee, Chun-Yue I., Meyer, Colin J., Proksch, Joel W., Sonis, Stephen T., Ward, Keith W.

“…Free radicals produced during cancer radiotherapy often leads to dermatitis, with the insult ranging from mild erythema to moist desquamation and ulceration…”
Get full text

Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis by Reisman, Scott A., Ferguson, Deborah A., Lee, Chun‐Yue I., Proksch, Joel W.

“…Omaveloxolone is a potent activator of Nrf2, a master transcriptional regulator of a multitude of cytoprotective functions, including antioxidative,…”
Get full text

Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates by Reisman, Scott A, Gahir, Sarabjit S, Lee, Chun-Yue I, Proksch, Joel W, Sakamoto, Mitsumasa, Ward, Keith W

“…Omaveloxolone is a synthetic oleanane triterpenoid that pharmacologically activates Nrf2, a master transcription factor that regulates genes with…”
Get full text

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors by Creelan, Ben C, Gabrilovich, Dmitry I, Gray, Jhanelle E, Williams, Charles C, Tanvetyanon, Tawee, Haura, Eric B, Weber, Jeffrey S, Gibney, Geoffrey T, Markowitz, Joseph, Proksch, Joel W, Reisman, Scott A, McKee, Mark D, Chin, Melanie P, Meyer, Colin J, Antonia, Scott J

“…Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I…”
Get full text

Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application by Donnenfeld, Eric D., MD, Comstock, Timothy L., OD, MS, Proksch, Joel W., PhD

“…Purpose To determine the concentrations of besifloxacin, moxifloxacin, and gatifloxacin in human aqueous humor after topical instillation of commercially…”
Get full text

Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin by Reisman, Scott A., Lee, Chun-Yue I., Meyer, Colin J., Proksch, Joel W., Ward, Keith W.

“…RTA 408 is a member of the synthetic oleanane triterpenoid class of compounds known to potently activate the cytoprotective transcription factor Nrf2. Because…”
Get full text

A rapid and sensitive LC/MS/MS assay for the quantitation of brimonidine in ocular fluids and tissues by Jiang, Sherwin, Chappa, Arvind K., Proksch, Joel W.

“…We report here the development and validation of an LC/MS/MS method for the rapid and accurate quantitation of brimonidine in ocular tissues and fluids using…”
Get full text

Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits by Proksch, Joel W, Ward, Keith W

“…The purpose of this investigation was to evaluate the ocular pharmacokinetic/pharmacodynamic (PK/PD) relationship for besifloxacin, moxifloxacin, and…”
Get more information

Ocular Pharmacokinetics of Mapracorat, a Novel, Selective Glucocorticoid Receptor Agonist, in Rabbits and Monkeys by PROKSCH, Joel W, LOWE, Ezra R, WARD, Keith W

“…Mapracorat is a selective glucocorticoid receptor agonist in development for the treatment of a variety of ocular diseases. The purpose of this investigation…”
Get full text

Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers by Reisman, Scott A, Goldsberry, Angela R, Lee, Chun-Yue I, O'Grady, Megan L, Proksch, Joel W, Ward, Keith W, Meyer, Colin J

“…Topical application of the synthetic triterpenoid RTA 408 to rodents elicits a potent dermal cytoprotective phenotype through activation of the transcription…”
Get full text

Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography–tandem mass spectrometry by Arnold, Dana R., Granvil, Camille P., Ward, Keith W., Proksch, Joel W.

“…A rapid and sensitive method was developed using high-performance liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) for the quantification…”
Get full text

Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans by Proksch, Joel W, Granvil, Camille P, Siou-Mermet, Raphaële, Comstock, Timothy L, Paterno, Michael R, Ward, Keith W

“…Studies were conducted to evaluate the ocular penetration and systemic exposure to besifloxacin, a fluoroquinolone antibiotic, following topical ocular…”
Get more information

Cassette dosing pharmacokinetic studies for evaluation of ophthalmic drugs for posterior ocular diseases by Proksch, Joel W, Ward, Keith W

“…The purpose of this investigation was to evaluate the utility of cassette dosing as a means for increasing throughput and decreasing animal usage for…”
Get more information

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration by Torkildsen, Gail, Proksch, Joel W, Shapiro, Aron, Lynch, Stephanie K, Comstock, Timothy L

“…To evaluate the pharmacokinetic properties of besifloxacin, gatifloxacin, and moxifloxacin in the conjunctival tissue of healthy volunteers after topical…”
Get full text

The use of the African green monkey as a preclinical model for ocular pharmacokinetic studies by Glogowski, Shellise, Ward, Keith W, Lawrence, Matthew S, Goody, Robin J, Proksch, Joel W

“…This investigation evaluated the ocular and systemic pharmacokinetics of besifloxacin in African green monkeys compared with cynomolgus monkeys following…”
Get more information

DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY by WARD, Keith W, STELMAN, Gary J, MORGAN, Jayme A, ZEIGLER, Kelli S, AZZARANO, Leonard M, KEHLER, Jonathan R, MCSURDY-FREED, Jeanelle E, PROKSCH, Joel W, SMITH, Brian R

“…The effect of P-glycoprotein (Pgp) and/or CYP3A on the disposition of xenobiotics has been extensively investigated and is often of interest during drug…”
Get full text

Nonclinical safety and pharmacokinetics of intravitreally administered human-derived plasmin in rabbits and minipigs by Proksch, Joel W, Driot, Jean-Yves, Vandeberg, Pete, Ward, Keith W

“…The use of plasmin for pharmacologic vitreolysis and the creation of a posterior vitreous detachment offers several potential advantages over surgery. The…”
Get more information

A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats by Hardin, J Shane, Wessinger, William D, Wenger, Galen R, Proksch, Joel W, Laurenzana, Elizabeth M, Owens, S Michael

“…These studies tested the hypothesis that a single dose of high-affinity anti-phencyclidine monoclonal antibody (anti-PCP mAb) provides long-term protection…”
Get more information

Development of an in Vivo Preclinical Screen Model to Estimate Absorption and Bioavailability of Xenobiotics by WARD, Keith W, PROKSCH, Joel W, LEVY, Mark A, SMITH, Brian R

“…The purpose of this study was to develop an in vivo screening method for rapid preclinical characterization of absorption and bioavailability of large numbers…”
Get full text